There is an unmet clinical need to manage heart failure with preserved ejection fraction in people with rheumatoid arthritis (RA). One hurdle is the absence of preclinical models to study pathology and pharmacology in settings of inflammatory arthritis. In addition, there is mixed clinical evidence on the effect of current RA therapeutics, such as anti-interleukin-6 (IL-6) therapy, on the incidence of diastolic dysfunction and heart failure in RA patients. We have used a transgenic mouse model (K/BxN F1 colony) where inflammatory arthritis develops prior to cardiac dysfunction. Polyarthritis was scored and paw volumes measured by plethysmometry. Heart functionality was assessed by echocardiography and plasma IL-6 was measured by ELISA. An anti-IL-6 receptor monoclonal antibody, MR16-1, was given after joint disease onset. Cardiac cell numbers were quantified by flow cytometry, along with phenotypic characterization of monocytes, macrophages and fibroblasts. In addition, the expression of selected inflammatory genes was quantified by qPCR. K/BxN F1 mice displayed higher IL-6 plasma levels than control mice, specifically after joint disease onset and prior to overt alterations in cardiac function. Treatment of arthritic K/BxN F1 male and female mice with MR16-1 resulted in a modest reduction (~ 15%) in joint disease whereas the development of diastolic dysfunction (monitored as left atrial area, E/A and e’/a’ ratios) was prevented. These functional improvements in the heart were accompanied by a significant reduction in pro-inflammatory gene expression (e.g., Il1 , Il6 ), decreased recruitment of classical monocytes (CCR2⁺Ly6C⁺), a lower number of pro-inflammatory macrophages (Gal-3⁺MHCII⁺CD206⁻), and reduced presence of pro-inflammatory cardiac fibroblasts (Thy1.2⁺podoplanin⁺). Treatment of arthritic mice with an antibody that blocks IL-6 signalling is effective in preventing functional alterations of the heart, likely consequent to regulation of monocyte recruitment, and reductions in numbers of pro-inflammatory macrophages and fibroblasts. These preclinical data could prompt specific studies to determine the efficacy of anti-IL-6 therapy in patients at increased risk of cardiac alterations that lead to heart failure.
Christoforou et al. (Mon,) studied this question.